ERNA · Ernexa Therapeutics Inc.
$4.74
-0.16 (-3.17%)
At close · Aug 27
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“we evaluated whether there are conditions and events, considered in the aggregate, that are known and reasonably knowable that would raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued. As of August 4, 2026, we had approximately $7.4 million in cash, which is less than that needed to affect our current operating plan and forecasted cash requirements for the next twelve months. However, we expect that our ability to access additional capital under our ATM will cover shortfalls in our cash resources over the next twelve months from the issuance date of these financial statements.”View the 10-Q filed Aug 6, 2026
Market Cap
$7.73M
Shares
1.63M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Allen Wolff | Former Chief Executive Officer | $594,040 |
| Sandra Gurrola | Vice President of Finance | $374,246 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Allen Wolff | Former Chief Executive Officer | $302,200 |
| Sandra Gurrola | Vice President of Finance | $205,396 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Sandra Gurrola | Senior Vice President of Finance | Resigned | 2026-06-26 |
| Dr. Elena Ratner | the Board | Appointed | 2025-01-10 |
| Dorothy Clarke | Board of Directors | Resigned | 2025-01-10 |
| Peter Cicala | member of the Board | Appointed | 2024-02-16 |
| Sanjeev Luther | member of the Company's Board of Directors | Appointed | 2023-12-20 |
| Sanjeev Luther | member of the Company's Board of Directors | Appointed | 2023-12-20 |
| Sanjeev Luther | President and Chief Executive Officer (and principal executive officer) | Appointed | 2023-12-20 |
| James Bristol | chairman of the Board | Appointed | 2023-12-20 |
| Dr. Matthew Angel | President and Chief Executive Officer | Resigned | 2023-12-20 |
| Dr. James Bristol | director | Appointed | 2023-11-01 |
| Gregory Fiore | board of directors | Resigned | 2023-10-05 |
| Dorothy J. Clarke | director | Appointed | 2023-08-31 |
| Richard W. Wagner | Director | Resigned | 2023-08-10 |
| Brant C. Binder | Director | Resigned | 2023-08-10 |
| Dr. Matthew Angel | President and Chief Executive Officer (principal executive officer) | Appointed | 2023-08-10 |
| Dr. Matthew Angel | Director | Resigned | 2023-08-10 |
| Dr. Matthew Angel | President and Chief Executive Officer | Resigned | 2023-08-10 |
| Richard W. Wagner | director | Appointed | 2023-07-11 |
| Brant C. Binder | director | Appointed | 2023-07-11 |
| Charles Cherington | Board of Directors | Resigned | 2023-07-11 |
| Nicholas Singer | Board of Directors | Resigned | 2023-07-11 |
| Andrew Jackson | Chief Financial Officer | Resigned | 2023-05-05 |
| Sandra Gurrola | principal financial officer | Appointed | 2023-05-05 |
| Dr. Roger Sidhu | Chief Medical Officer | Resigned | 2023-01-26 |
| Dr. Matthew Angel | President and Chief Executive Officer | Appointed | 2023-01-04 |
Key facts
CIK
748592
CUSIP
114082407
13F (30d)
14 filings
14 filers
Visit website
Investor relations